Tranylcypromine (Parnate)
Irreversible, non-selective monoamine oxidase (MAO-A and MAO-B) inhibitor with an amphetamine-like cyclopropylamine structure. More stimulating than phenelzine due to structural similarity to amphetamine and its mild dopamine-releasing properties. Despite a short plasma half-life (~2.5 h), the irreversible MAO inactivation produces a pharmacodynamic effect lasting 2-3 weeks. Particularly effective in anergic, atypical, and treatment-resistant depression. Carries ALL the same SERIOUS serotonin syndrome and tyramine hypertensive crisis risks as phenelzine, with the additional caution that its amphetamine-like properties confer a risk of abuse and hypertensive effects with sympathomimetics.
Projected serum levels — 30 mg, once daily
Maintenance schedule: 30 mg once daily (oral).
Modeled steady state after ~1 days: peak ≈ 4.1 mg, trough ≈ 0.010 mg body load. Population-based estimate over 15 days for a 30 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- MAOI Antidepressant
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 2.5 h
- Common dose
- 30 mg
- Suggested maximum
- 60 mg/day
- Reference dose range
- 10–60 mg (single dose)
- Suggested cadence
- once daily
- Validated against
- 30 mg oral — Cmax 0.050 mg/L at 1.5 h
Documented interactions
-
danger
1P-LSD (1-Propionyl-LSD) + Tranylcypromine (Parnate)
1P-LSD (1-Propionyl-LSD) and Tranylcypromine (Parnate) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
-
danger
25I-NBOMe + Tranylcypromine (Parnate)
25I-NBOMe and Tranylcypromine (Parnate) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
-
danger
2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Tranylcypromine (Parnate)
2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Tranylcypromine (Parnate) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…
-
danger
2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Tranylcypromine (Parnate)
2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Tranylcypromine (Parnate) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…
-
danger
3-MeO-PCP (3-Methoxyphencyclidine) + Tranylcypromine (Parnate)
3-MeO-PCP (3-Methoxyphencyclidine) and Tranylcypromine (Parnate) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
-
danger
4-AcO-DMT (Psilacetin) + Tranylcypromine (Parnate)
4-AcO-DMT (Psilacetin) and Tranylcypromine (Parnate) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
Serum checks 108 modeled interaction pairings for tranylcypromine (parnate) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Tranylcypromine versus imipramine in anergic bipolar depression
Controlled trial demonstrating tranylcypromine's statistically significant superiority over imipramine (a TCA) in anergic bipolar depression, establishing MAOIs as a key treatment option for bipolar depression with…
-
A double-blind comparison of phenelzine and tranylcypromine in atypical depression
Head-to-head RCT comparing the two major irreversible MAOIs in atypical depression, finding comparable antidepressant efficacy but tranylcypromine producing more rapid response and greater activating/stimulating…
-
The treatment of depressive conditions with tranylcypromine (Parnate): a review
Seminal review by a pioneer in MAOI clinical research, documenting tranylcypromine's efficacy profile, the importance of tyramine dietary restrictions, and the clinical observation that MAOI response is often most…
3 published studies referenced in the app, each with a plain-language summary.